The term gastroparesis literally means “stomach paralysis.” Gastroparesis could be defined as a condition of collective symptoms of nausea and vomiting associated with bloating and early satiety plus or minus upper abdominal pain, caused by delayed gastric emptying in the absence of mechanical obstruction. In the absence of mechanical obstruction, gastric stasis can occur due to abnormalities in the process of normal gastrointestinal motor function. It is a series of complex events that require coordination of the parasympathetic and sympathetic nervous systems, neurons, and pacemaker cells within the stomach and intestine, along with the smooth muscle cells of the gut.
Various conditions have correlations with gastroparesis; the majority of cases are idiopathic, diabetic, medication-induced, or postsurgical. One of the studies done at a tertiary care center categorized the etiologies in 146 patients: 36% idiopathic, 29% diabetic, 13% postgastric surgery, 7.5% Parkinson disease, 4.8% collagen vascular disorders, 4.1% intestinal pseudoobstruction, and 6% miscellaneous causes. A wide variety of neurologic disorders, as mentioned below, can affect gastrointestinal motility by altering the parasympathetic or sympathetic nerve supply to the gastrointestinal (GI) tract. Etiology of gastroparesis categorizes as follows:
Diabetic patients at risk of developing gastroparesis include type 1 diabetes, long duration of the disease, poorly controlled blood sugars with higher fluctuations, and associated other autonomic neuropathic complications. As noted in other diabetes-related complications, oxidative damage of these tissues is the prominent mechanism in gastroparesis. In patients with diabetic gastroparesis, several abnormal physiological functions have been noted, mainly resulting from autonomic dysfunction and/or intrinsic nervous system dysfunction. This neuropathic malfunction and coordination result in reduced frequency of antral muscle contractions, impairing postprandial accommodation reflex, thereby affecting gastric emptying.
Post-surgical etiology: Any surgery involving the esophagus, stomach, duodenum, and pancreas could pose a risk of injury to the vagal nerve. Vagus nerve controls contraction and smooth muscles of the stomach and sensory pathways that coordinate forward propulsion of gastric contents. Hence, injury of the vagus nerve delays gastric emptying. Postsurgical gastroparesis may develop immediately after the surgery or months to years after the surgery occurred. Common surgical procedures associated with this complication include Nissen fundoplication, gastrectomy, pancreatic cancer cryoablation, pancreatoduodenectomy. Rarely gastroparesis has been reported in gynecological surgeries involving the lower abdomen.
The epidemiology of gastroparesis is unclear and difficult to estimate due to the relatively weak correlation of symptoms with gastric emptying resulting in a high rate of underdiagnosis. But in one of the largest population-based studies, about 3604 cases of possible gastroparesis were evaluated, of which 83 patients classified as definite gastroparesis, 127 patients as probable gastroparesis. The incidence was 2.4 for men and 9.8 for women after age adjustment. The prevalence of definite gastroparesis as of 2007, January 1, was 9.6 for men and 37.8 for women. The incidence is higher in women than men and especially more prevalent in younger age groups. Age-adjusted female to male ratio of 3.9 to 1.
Abnormal coordination of the motor functions of the stomach results in delayed gastric emptying; this could be due to various pathology and can affect different areas of the stomach like fundus, body, and antrum. In patients with diabetes, the pathophysiology is noted at various levels, including intrinsic and extrinsic neurons, smooth muscle, and interstitial cells of Cajal. Oxidative damage results in abnormal motor coordination in the antral region, causing dysfunctional contractions and impaired postprandial gastric accommodation phenomenon. Coordinated antral motor function is crucial for grinding, mixing, and gastric emptying of solids, abnormalities of which result in the accumulation of indigestible food, eventually forming a bezoar. The most commonly observed pathophysiology in neuropathic disorder is a lower frequency of normal amplitude antral motor contractions. But rarely, in infiltrative disorders like systemic sclerosis, a low-intensity amplitude of antral contractions is observed. In postvagotomy and post gastric resection patients, phasic contractility and accommodation response of the stomach are impaired.
Histopathologically, gastroparesis is associated with a reduced number of autonomic ganglia and ganglion cells in addition to inflammatory changes resulting in abnormal gastric myoelectric motor functions. In a study done in patients with refractory gastroparesis evaluating gastric neuromuscular histopathology, researchers observed the following findings: lymphocytic infiltration of the intermyenteric plexus, fibrosis in the inner circular layer and outer longitudinal layer, and decreased interstitial cells of Cajal were visible in the myenteric plexus. Also, fewer ganglia and ganglion cells were present in diabetic gastroparesis.
History: Gastroparesis is a heterogeneous disorder; its etiology affects symptoms and severity. Patients with gastroparesis can present with various symptoms. The predominant symptom may vary depending on the underlying etiology. Overall, nausea is present in about 93 percent of cases, vomiting in 68 to 84 percent, abdominal pain in 46 to 90 percent, early satiety 60 to 86 percent. Other symptoms include postprandial fullness, bloating, and weight loss in severe and persistent cases. Characteristically vomitus may contain food ingested several hours ago. There are similarities and differences in the clinical characteristics of Diabetic gastroparesis and Idiopathic gastroparesis. Patients with idiopathic gastroparesis reported more symptoms of early satiety, postprandial fullness, and abdominal pain as compared with patients with diabetic gastroparesis. Patients with diabetic gastroparesis had more severe retching and vomiting. Even though abdominal pain is a frequent complaint in patients with gastroparesis, it is rarely the predominant symptom (present in about 18 percent). In patients whose principal symptom is abdominal pain, other causes merit consideration. On physical examination, providers may elicit epigastric distention or tenderness, but no guarding or rigidity. Patients may have signs of the underlying disorder causing gastroparesis.
Gastroparesis gets evaluated in clinical practice through the recognition of the clinical symptoms and documentation of delayed gastric emptying. The goal of the evaluation is to exclude a mechanical obstruction and establish the diagnosis of gastroparesis by an assessment of gastric motility. Robust patient history should point to suspicion of a possible diagnosis. Gastroparesis should be a suspicion in patients with chronic nausea, vomiting, early satiety, postprandial fullness, abdominal pain, or bloating. The next step would be ruling out mechanical obstruction, which could be done with a careful upper GI endoscopy to rule out malignancy or strictures due to peptic ulcer disease.
Imaging modalities like computed tomographic (CT) scan or magnetic resonance imaging (MRI) abdomen may be needed to exclude mechanical obstruction. After ruling out mechanical causes, gastric emptying studies (GES) are performed by scintigraphy to confirm the presence of delayed gastric emptying of solids. A solid or liquid radioisotope containing meal may be used to measure gastric emptying. Upon scintigraphy, based on the gastric retention of contents at the end of four hours, gastroparesis could be graded into mild (less than 15 percent), moderate (15 to 35 percent), and severe (over 35 percent). Symptoms of gastroparesis may also be quantifiable via GCSI (gastroparesis cardinal symptom index), a questionnaire based on the severity of symptoms postprandial fullness, early satiety, nausea vomiting, and bloating. As compared to the traditional method of GES (testing for 2 hours or less), the sensitivity of the test results could increase by extending the imaging of solid gastric emptying to 4 hours. In patients with normal solid gastric emptying, adding a liquid GES study could further increase its sensitivity to diagnose gastroparesis.
Management of gastroparesis should include a holistic approach to target different aspects of the disease such as assessment of nutritional status, measures to correct fluid, electrolyte, and nutritional deficiencies, relief of symptoms of gastroparesis, improving gastric emptying, recognize and rectify the underlying cause of gastroparesis to prevent progressing of the disease, e.g., tight glycemic control in diabetes, stopping causative medications.
Diet modifications: Small Meal size could limit emptying time and help symptom alleviation. Patients may need to eat 4 or 5 times per day to compensate for the small meal size. Carbonated drinks like soda and beer could release carbon dioxide, which can aggravate gastric distention. Smoking or high doses of alcohol can decrease antral contractility and impair gastric emptying. The nutritional state of the patient should be promptly assessed, utilizing ancillary service consultation. If oral intake is not adequate, then enteral nutrition via jejunostomy tube should be considered. Parenteral nutrition is rarely required.
Medical treatment: As needed antiemetics such as prochlorperazine (5 to 10 mg up to 3 times a day), diphenhydramine (12.5 mg up to 3 or 4 times a day) and ondansetron (4 or 8 mg up to 3 times a day) can provide symptomatic relief in gastroparesis. Metoclopramide, a prokinetic medication, is the only FDA approved drug for gastroparesis. It is usually started with 5 mg three times a day, fifteen minutes before meals. It can be titrated up to 40 mg per day but need very close monitoring for adverse effects. Also, the duration of treatment approved by the FDA is 12 weeks due to the possibility of severe side effects. Common side effects include anxiety, restlessness, hyperprolactinemia, and QT prolongation. Metoclopramide has a black box warning for extrapyramidal symptoms like dystonia and tardive dyskinesia in about 1 percent of patients. Other off-label medications aimed at symptom relief include domperidone, erythromycin (short term), tegaserod (5-HT4 partial agonist), and centrally acting antidepressants. Domperidone is a dopamine 2 antagonist, works more like metoclopramide to improve gastric emptying and decrease nausea and vomiting. The FDA restricts domperidone use in the United States, and it is currently under review as an investigational drug. Domperidone is usually started at 10mg three a day, and dosing could potentially increase to 20mg per dose. Significant adverse effects are cardiac arrhythmias and hyperprolactinemia. It is a recommendation to monitor the QT interval while being on domperidone, avoid use for QT over 450 ms. Drug interactions may occur with cisapride, azole antifungals, and antiretrovirals. Patients resistant to metoclopramide and domperidone could have treatment with erythromycin, a macrolide antibiotic that has shown to stimulate high-amplitude gastric fundal peristaltic contractions, thereby improving symptoms in acute exacerbation. The Route of administration is intravenous (3 g/kg every eight hours) in acute cases and high dose oral administration (250 to 500 mg three times a day) for maintenance. But erythromycin is prone to tachyphylaxis (decrease in response quickly due to desensitization), and so its use is restricted to a maximum of four weeks at a time. Common side effects of erythromycin include GI toxicity, ototoxicity, bacterial resistance, QT prolongation.
Non-medical approaches: Gastric electrical stimulation (GES) has shown to relieve symptoms, mainly vomiting frequency and the need for nutrition supplementation. In patients with refractory symptoms even after trial of the medications mentioned above, GES is considered as compassionate treatment approved for diabetic and idiopathic gastroparesis patients as a humanitarian exemption device. Diabetic patients respond more effectively than other groups of gastroparesis patients. Implantation of GES stimulator needs surgical procedure either via laparotomy or laparoscopic approach. The device consists of a pair of leads, implanted in the muscularis propria about 10 cm proximal to the pylorus, and then connected to a pulse generator. Risks of GES include infection of the device, lead migration, and perforation, necessitating repeat surgical procedures. Also may need battery replacement about every ten years or so. Other available interventions, with no substantial evidence, that are under consideration are venting gastrostomy or feeding jejunostomy, intra-pyloric botulinum toxin injection (not shown to be effective in randomized controlled trials), partial gastrectomy and pyloroplasty (used rarely, only in carefully selected patients).
Future prospects: Multiple prospective treatments have been considered or being investigated for the management of gastroparesis. Granisetron, a 5-HT3 antagonist, administered as a transdermal patch, has improved gastroparesis symptoms of nausea and vomiting, as evident in a prospective study. Similarly, a randomized control trial involving aprepitant, a neurokinin-1 receptor antagonist, showed positive results of symptom improvement in gastroparesis patients. A scopolamine patch has undergone an evaluation with no significant effects. Also, research is ongoing studying the effects of transcutaneous acupuncture (TEA) in gastroparesis. Cannabinoids (dronabinol) have been considered in the treatment of gastroparesis symptoms, but there are no clinical trials reported. Cannabinoids are likely to be ineffective since they are known to delay gastric emptying. Attention should be given to the development of new effective therapies for symptomatic control. Relamorelin (a pentapeptide ghrelin receptor agonist) prucalopride and velusetrag (both are 5HT-4 receptor agonists) and metoclopramide nasal spray are investigational therapies undergoing evaluation in patients with gastroparesis.
Symptoms of nausea and vomiting are so nonspecific that they could have a wide variety of differential diagnoses. But the following conditions mentioned below could pose a very similar presentation to gastroparesis.
1. Gastric Outlet Obstruction: very similar presentation but with underlying mechanical obstruction.
2. Cyclical vomiting syndrome: Typically has recurrent cyclical episodes of intractable nausea and vomiting lasting few hours to days.
3. Functional dyspepsia: diagnosed by Rome IV criteria for functional dyspepsia.
5. Psychiatric diseases – many psychiatric conditions, including anxiety neurosis, eating disorders like anorexia nervosa, bulimia could have persistent upper GI symptoms confusing with gastroparesis. It could get complicated, especially as some psychiatric medications can cause delayed gastric emptying.
Gastroparesis is a rather uncommon condition in the community but can be associated with poor outcome. The natural history of gastroparesis is unclear and poorly outlined. In one small study of 20 patients with diabetes followed for 12 years, gastric emptying symptoms were reasonably stable. In another study, 86 patients with diabetes were studied; after adjusting for comorbidities, gastroparesis symptoms did not correlate with mortality. In contrast, results from a study done at a tertiary center suggested 7% of gastroparesis patients had died, and 22% of patients needed long-term enteral or parenteral nutrition after six years follow up; this indicates gastroparesis could be associated with significant mortality and morbidity. Controlled community studies for the prognosis of gastroparesis are needed, and data from tertiary care hospitals may not represent the disease in the general population. Postviral gastroparesis often improves over one year.
The incidence of complications from gastroparesis could vary according to underlying etiology. Longstanding patients of gastroparesis will most likely suffer from the following complications.
Bezoar - a solid mass of indigestible material that accumulates in the stomach, eventually mechanical obstruction. Bezoars can cause loss of appetite, weight loss, and a feeling of fullness. They can also lead to gastric ulcers, GI bleeding, and bowel obstruction. Usually diagnosed by endoscopy and large bezoars often require surgical intervention.
Patients with gastroparesis frequently present challenging clinical, diagnostic, and therapeutic problems. The nature of the disease itself could be a significant deterrence in obtaining appropriate healthcare. Systematic education targeting at different levels should help tackle this issue. Gastroparesis is a common diagnosis among diabetic patients. But it can affect people without diabetes or any attributable underlying disorder. It also can occur after viral gastroenteritis. All people with diabetes and other appropriate patients should receive education about symptoms and the natural history of gastroparesis. Diagnosed patients should have a detail education about diet and lifestyle modifications, including eating multiple small meals, avoiding alcohol, smoking, and fizzy drinks, which could cause bloating. Due to the chronicity of symptoms and the lack of definitive treatment options, plus the social implications it can cause, gastroparesis could drastically affect the quality of life of the patients. This aspect could be the most significant deterrence in the management of gastroparesis patients.
The number of gastroparesis-related hospitalizations has been increasing in the United States, and the economic impact of gastroparesis-related hospitalizations is significant and may be increasing. Due to chronicity and idiopathic etiology in most cases, gastroparesis patients could face social stigma and become medication dependent.
An interprofessional team approach is essential to improve the morbidity of the disorder. The pharmacist should educate the patient on medications that can help improve gastric motility but at the same time, warn them about the adverse effects. The diabetes educator nurse should inform the patient on control of blood glucose, and the dietitian should recommend smaller meals at each setting. Patients should be encouraged to eat a healthy diet and consume ample water. Any food that triggers gastroparesis should be avoided. Healthy body weight and regular exercise are also recommended interventions. These examples demonstrate how an interprofessional team approach to gastroparesis can improve patient outcomes [Level 5]
One of the main aspects overlooked is the quality of life of the patient. Both patient and healthcare provider education plays a critical role in identifying and managing patients of gastroparesis. Most parts of the diagnostic approach to gastroparesis and recommendations regarding its treatment have their basis on the cumulative experience and opinions of physicians who specialize in the care of these patients. A more controlled investigation is needed to validate any therapeutic algorithm in managing this challenging condition.
Interprofessional team dynamics can bring about optimal patient results. [Level 5]
|||Camilleri M,Parkman HP,Shafi MA,Abell TL,Gerson L, Clinical guideline: management of gastroparesis. The American journal of gastroenterology. 2013 Jan; [PubMed PMID: 23147521]|
|||Lacy BE,Parkman HP,Camilleri M, Chronic nausea and vomiting: evaluation and treatment. The American journal of gastroenterology. 2018 May; [PubMed PMID: 29545633]|
|||Soykan I,Sivri B,Sarosiek I,Kiernan B,McCallum RW, Demography, clinical characteristics, psychological and abuse profiles, treatment, and long-term follow-up of patients with gastroparesis. Digestive diseases and sciences. 1998 Nov; [PubMed PMID: 9824125]|
|||Parkman HP,Yates K,Hasler WL,Nguyen L,Pasricha PJ,Snape WJ,Farrugia G,Koch KL,Calles J,Abell TL,McCallum RW,Lee L,Unalp-Arida A,Tonascia J,Hamilton F, Similarities and differences between diabetic and idiopathic gastroparesis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2011 Dec; [PubMed PMID: 21871247]|
|||Pasha SF,Lunsford TN,Lennon VA, Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine. Gastroenterology. 2006 Nov; [PubMed PMID: 17101331]|
|||Dhamija R,Tan KM,Pittock SJ,Foxx-Orenstein A,Benarroch E,Lennon VA, Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2008 Sep; [PubMed PMID: 18599359]|
|||Sigurdsson L,Flores A,Putnam PE,Hyman PE,Di Lorenzo C, Postviral gastroparesis: presentation, treatment, and outcome. The Journal of pediatrics. 1997 Nov; [PubMed PMID: 9403659]|
|||Bityutskiy LP,Soykan I,McCallum RW, Viral gastroparesis: a subgroup of idiopathic gastroparesis--clinical characteristics and long-term outcomes. The American journal of gastroenterology. 1997 Sep; [PubMed PMID: 9317072]|
|||Parkman HP,Hasler WL,Fisher RS, American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology. 2004 Nov; [PubMed PMID: 15521026]|
|||Neshatian L,Gibbons SJ,Farrugia G, Macrophages in diabetic gastroparesis--the missing link? Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2015 Jan [PubMed PMID: 25168158]|
|||Quigley EM, Other forms of gastroparesis: postsurgical, Parkinson, other neurologic diseases, connective tissue disorders. Gastroenterology clinics of North America. 2015 Mar [PubMed PMID: 25667024]|
|||Meng H,Zhou D,Jiang X,Ding W,Lu L, Incidence and risk factors for postsurgical gastroparesis syndrome after laparoscopic and open radical gastrectomy. World journal of surgical oncology. 2013 Jun 19 [PubMed PMID: 23782501]|
|||Talley NJ,Locke GR 3rd,Lahr BD,Zinsmeister AR,Tougas G,Ligozio G,Rojavin MA,Tack J, Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut. 2006 Jul; [PubMed PMID: 16322108]|
|||Jung HK,Choung RS,Locke GR 3rd,Schleck CD,Zinsmeister AR,Szarka LA,Mullan B,Talley NJ, The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006. Gastroenterology. 2009 Apr; [PubMed PMID: 19249393]|
|||Kumar A,Attaluri A,Hashmi S,Schulze KS,Rao SS, Visceral hypersensitivity and impaired accommodation in refractory diabetic gastroparesis. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2008 Jun [PubMed PMID: 18282170]|
|||Camilleri M,Brown ML,Malagelada JR, Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology. 1986 Jul [PubMed PMID: 3710086]|
|||Thumshirn M,Bruninga K,Camilleri M, Simplifying the evaluation of postprandial antral motor function in patients with suspected gastroparesis. The American journal of gastroenterology. 1997 Sep [PubMed PMID: 9317071]|
|||Azpiroz F,Malagelada JR, Gastric tone measured by an electronic barostat in health and postsurgical gastroparesis. Gastroenterology. 1987 Apr [PubMed PMID: 3556999]|
|||Heckert J,Thomas RM,Parkman HP, Gastric neuromuscular histology in patients with refractory gastroparesis: Relationships to etiology, gastric emptying, and response to gastric electric stimulation. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2017 Aug [PubMed PMID: 28374487]|
|||Hoogerwerf WA,Pasricha PJ,Kalloo AN,Schuster MM, Pain: the overlooked symptom in gastroparesis. The American journal of gastroenterology. 1999 Apr; [PubMed PMID: 10201478]|
|||Camilleri M, Management of patients with chronic abdominal pain in clinical practice. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2006 Jul; [PubMed PMID: 16771765]|
|||Sachdeva P,Kantor S,Knight LC,Maurer AH,Fisher RS,Parkman HP, Use of a high caloric liquid meal as an alternative to a solid meal for gastric emptying scintigraphy. Digestive diseases and sciences. 2013 Jul; [PubMed PMID: 23589143]|
|||Revicki DA,Rentz AM,Dubois D,Kahrilas P,Stanghellini V,Talley NJ,Tack J, Gastroparesis Cardinal Symptom Index (GCSI): development and validation of a patient reported assessment of severity of gastroparesis symptoms. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2004 May [PubMed PMID: 15129893]|
|||Revicki DA,Rentz AM,Dubois D,Kahrilas P,Stanghellini V,Talley NJ,Tack J, Development and validation of a patient-assessed gastroparesis symptom severity measure: the Gastroparesis Cardinal Symptom Index. Alimentary pharmacology & therapeutics. 2003 Jul 1 [PubMed PMID: 12848636]|
|||Antoniou AJ,Raja S,El-Khouli R,Mena E,Lodge MA,Wahl RL,Clarke JO,Pasricha P,Ziessman HA, Comprehensive radionuclide esophagogastrointestinal transit study: methodology, reference values, and initial clinical experience. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015 May [PubMed PMID: 25766893]|
|||Rao AS,Camilleri M, Review article: metoclopramide and tardive dyskinesia. Alimentary pharmacology & therapeutics. 2010 Jan [PubMed PMID: 19886950]|
|||Midani D,Parkman HP, Granisetron Transdermal System for Treatment of Symptoms of Gastroparesis: A Prescription Registry Study. Journal of neurogastroenterology and motility. 2016 Oct 30 [PubMed PMID: 27400689]|
|||Pasricha PJ,Yates KP,Sarosiek I,McCallum RW,Abell TL,Koch KL,Nguyen LAB,Snape WJ,Hasler WL,Clarke JO,Dhalla S,Stein EM,Lee LA,Miriel LA,Van Natta ML,Grover M,Farrugia G,Tonascia J,Hamilton FA,Parkman HP, Aprepitant Has Mixed Effects on Nausea and Reduces Other Symptoms in Patients With Gastroparesis and Related Disorders. Gastroenterology. 2018 Jan [PubMed PMID: 29111115]|
|||Shin A,Camilleri M,Busciglio I,Burton D,Smith SA,Vella A,Ryks M,Rhoten D,Zinsmeister AR, The ghrelin agonist RM-131 accelerates gastric emptying of solids and reduces symptoms in patients with type 1 diabetes mellitus. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2013 Nov; [PubMed PMID: 23639598]|
|||Manabe N,Wong BS,Camilleri M, New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders. Expert opinion on investigational drugs. 2010 Jun; [PubMed PMID: 20408739]|
|||Sanger GJ,Westaway SM,Barnes AA,Macpherson DT,Muir AI,Jarvie EM,Bolton VN,Cellek S,Näslund E,Hellström PM,Borman RA,Unsworth WP,Matthews KL,Lee K, GSK962040: a small molecule, selective motilin receptor agonist, effective as a stimulant of human and rabbit gastrointestinal motility. Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society. 2009 Jun; [PubMed PMID: 19374732]|
|||Avalos DJ,Sarosiek I,Loganathan P,McCallum RW, Diabetic gastroparesis: current challenges and future prospects. Clinical and experimental gastroenterology. 2018 [PubMed PMID: 30310300]|
|||Stanghellini V,Chan FK,Hasler WL,Malagelada JR,Suzuki H,Tack J,Talley NJ, Gastroduodenal Disorders. Gastroenterology. 2016 May; [PubMed PMID: 27147122]|
|||O'Brien MD,Bruce BK,Camilleri M, The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology. 1995 Apr; [PubMed PMID: 7698568]|
|||Chial HJ,Camilleri M,Williams DE,Litzinger K,Perrault J, Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics. 2003 Jan; [PubMed PMID: 12509570]|
|||Jones KL,Russo A,Berry MK,Stevens JE,Wishart JM,Horowitz M, A longitudinal study of gastric emptying and upper gastrointestinal symptoms in patients with diabetes mellitus. The American journal of medicine. 2002 Oct 15; [PubMed PMID: 12427492]|
|||Kong MF,Horowitz M,Jones KL,Wishart JM,Harding PE, Natural history of diabetic gastroparesis. Diabetes care. 1999 Mar; [PubMed PMID: 10097936]|